UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Zip Code) | ||
(Address of principal executive offices) |
Registrant’s telephone number, including area code: (
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 4, 2022, Collegium Pharmaceutical, Inc. issued a press release announcing its financial results for the quarterly period ended June 30, 2022. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K.
Item 7.01Regulation FD Disclosure.
On August 4, 2022, Collegium Pharmaceutical, Inc. released an earnings presentation. The presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
| |
No. | Description | |
99.1 | ||
99.2 | ||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Collegium Pharmaceutical, Inc. | ||
By: | /s/ Colleen Tupper | |
Colleen Tupper | ||
Executive Vice President and Chief Financial Officer | ||
Dated: August 4, 2022
Exhibit 99.1
Collegium Reports Second Quarter 2022 Financial Results
– Generated Record Net Revenue of $123.5 Million –
– BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million –
– Raises Full Year Adjusted EBITDA Guidance –
– Conference Call Scheduled for Today at 4:30 p.m. ET –
STOUGHTON, Mass., August 4, 2022 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.
“Following closing of the financially transformative acquisition of BDSI, the Collegium team successfully completed phase one, Seamless Integration, of our three-phase action agenda, effectively transitioning operations and achieving day-one commercial readiness. We remain on track to exceed targeted run rate synergies of at least $75 million,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “In July, we transitioned to phase two, Generate Momentum, and are focused on growing Belbuca® and Xtampza® ER prescriptions, and successfully renegotiating Xtampza ER contracts that will ensure gross-to-net of less than 65% beginning in January 2023. Phase three, Accelerate, begins in January 2023, and will be propelled by Xtampza ER revenue growth and Belbuca and Xtampza ER prescription growth, and bolstered by a fully synergized cost structure.”
“In the second quarter, our first full quarter post the BDSI acquisition, we delivered record revenue, leveraged our cost structure, generated significant operating cashflows, and paid down debt,” said Colleen Tupper, Chief Financial Officer of Collegium. “Our financial position is strong, and we remain focused on strategically deploying our capital to create value for our shareholders.”
First Half 2022 Business Highlights
| ● | Completed phase one, Seamless Integration, of the three-phase action agenda following the close of the BDSI acquisition |
| ● | Increased Collegium’s market share of the Branded ER market to 49.0% in June 2022 |
| ● | Grew Belbuca market share to 17.7% of the Branded ER market and Xtampza ER market share to 35.0% of the oxycodone ER market in June 2022 |
| ● | Transitioned BDSI core operations and achieved day-one commercial readiness following the close of the BDSI acquisition |
| ● | Executed a master settlement agreement resolving all 27-pending opioid industry-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United States |
| ● | Presented four poster presentations and one oral presentation on Elyxyb™ at the American Headache Society 64th Annual Scientific Meeting |
Financial Guidance for 2022
| ● | The Company updates its full-year 2022 guidance for Total Adjusted Operating Expenses and Total Adjusted EBITDA: |
| Prior | Updated |
| | |
Total Product Revenues | $450.0 to $465.0 million | Reaffirmed |
| | |
Total Adjusted Operating Expenses (Excluding Stock-Based Compensation and Acquisition Related Expenses) | $130.0 to $140.0 million | $125.0 to $135.0 million |
| | |
Total Adjusted EBITDA (Excluding Stock-Based Compensation and Acquisition Related Expenses) | $235.0 to $250.0 million | $245.0 to $255.0 million |
| | |
Financial Results for Quarter Ended June 30, 2022
| ● | Total net product revenues were $123.5 million for the quarter ended June 30, 2022 (the “2022 Quarter”), compared to $82.9 million for the quarter ended June 30, 2021 (the “2021 Quarter”) |
| ● | GAAP operating expenses were $41.3 million for the 2022 Quarter, compared to $33.8 million for the 2021 Quarter; Adjusted operating expenses, which exclude stock-based compensation expense of $5.7 million and acquisition expense of $3.6 million, were $32.0 million for the 2022 Quarter, compared to $27.3 million for the 2021 Quarter, which excluded stock-based compensation of $6.5 million |
| ● | Net loss for the 2022 Quarter was $5.2 million, or $0.15 loss per share (basic and diluted), compared to net income of $72.8 million, or $2.06 earnings per share (basic) and $1.79 earnings per share (diluted), which included the discrete tax benefit related to the release of the valuation allowance, for the 2021 Quarter; income from operations, excluding acquisition related expenses, was $14.7 million for the 2022 Quarter compared to $16.4 million for the 2021 Quarter |
| ● | Adjusted EBITDA for the 2022 Quarter was $71.2 million, compared to $40.1 million for the 2021 Quarter |
| ● | The Company exited the 2022 Quarter with a cash balance of $122.7 million |
Conference Call Information
The Company will host a conference call and live audio webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time. To access the conference call, please dial (877) 407- 8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Q2 2022 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Non-GAAP Financial Measures
To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures such as adjusted EBITDA and adjusted operating expenses. We use these non-GAAP financial measures to understand, manage and evaluate our business as we believe they provide additional information on the performance of our business. We believe that the presentation of these non-GAAP financial measures, taken in conjunction with our results under GAAP, provide analysts, investors, lenders and other third parties insight into our view and assessment of our ongoing operating performance. In addition, we believe that the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide supplementary information that may be useful to analysts, investors, lenders, and other third parties in assessing our performance and results from period to period. We report these non-GAAP financial measures to portray the results of our operations prior to considering certain income statement elements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP.
In our quarterly and annual reports, earnings press releases and conference calls, we may discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
There are several limitations related to the use of adjusted EBITDA rather than net income, which is the nearest GAAP equivalent, such as:
| ● | adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; |
| ● | we exclude stock-based compensation expense from adjusted EBITDA although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position; |
| ● | adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs; |
| ● | adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes; |
| ● | adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments; |
| ● | we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business; |
| ● | we exclude litigation settlements from adjusted EBITDA, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred; |
| ● | we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, and miscellaneous other acquisition expenses incurred; and |
| ● | we exclude recognition of the step-up basis in inventory from acquisitions as the amount and/or frequency of these expenses are not part of our underlying business. |
Adjusted Operating Expenses
Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.
The Company has not provided a reconciliation of its full-year 2022 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures because it is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense. These items are uncertain and depend on various factors that could have a material impact on GAAP net income and operating expenses for the guidance period.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our full-year 2022 financial guidance, including total projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations. Actual results may differ materially from management’s expectations and such forward-looking statements in this press release could be affected as a result of various important factors, including risks relating to, among others: risks related to the ability to realize the anticipated benefits of our acquisition of BDSI, including the possibility that
the expected benefits from the BDSI acquisition will not be realized or will not be realized within the expected time period; the risk that BDSI’s business will not be integrated successfully; unknown liabilities; risks related to future opportunities and plans for the products acquired with BDSI, including uncertainty of the expected financial performance of such products; the impact of the COVID-19 pandemic on our ability to conduct our business, reach our customers, and supply the market with our products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain and maintain regulatory approval of our products and any product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product; the size of the markets for our products and product candidates, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement, opioid-related or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P.; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Alex Dasalla
Head of Investor Relations
adasalla@collegiumpharma.com
Collegium Pharmaceutical, Inc.
Unaudited Selected Consolidated Balance Sheet Information
(in thousands)
| | June 30, | | December 31, | ||
|
| 2022 | | 2021 | ||
Cash and cash equivalents | | $ | 122,722 | | $ | 186,426 |
Accounts receivable, net | |
| 197,505 | | | 105,844 |
Inventory | |
| 77,769 | | | 17,394 |
Prepaid expenses and other current assets | |
| 11,778 | | | 5,879 |
Property and equipment, net | | | 19,965 | | | 19,491 |
Operating lease assets | |
| 7,257 | | | 7,644 |
Intangible assets, net | |
| 647,299 | | | 268,723 |
Restricted cash | |
| 2,547 | | | 2,547 |
Deferred tax assets | | | 28,571 | | | 78,042 |
Other noncurrent assets | |
| 67 | | | 87 |
Goodwill | | | 130,094 | | | — |
Total assets | | $ | 1,245,574 | | $ | 692,077 |
| | | | | | |
Accounts payable and accrued expenses | |
| 46,331 | | | 33,403 |
Accrued rebates, returns and discounts | |
| 246,719 | | | 196,996 |
Term notes payable | |
| 605,686 | | | 110,019 |
Convertible senior notes | | | 140,415 | | | 139,966 |
Operating lease liabilities | |
| 8,811 | | | 8,765 |
Shareholders’ equity | |
| 197,612 | | | 202,928 |
Total liabilities and stockholders’ equity | | $ | 1,245,574 | | $ | 692,077 |
Collegium Pharmaceutical, Inc.
Unaudited Condensed Statements of Operations
(in thousands, except share and per share amounts)
| Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
| 2022 | | 2021 | | 2022 | | 2021 | ||||
Product revenues, net | $ | 123,549 | | $ | 82,942 | | $ | 207,300 | | $ | 170,663 |
Cost of product revenues | | | | | | | | | | | |
Cost of product revenues (excluding intangible asset amortization) | | 33,684 | | | 15,908 | | | 50,016 | | | 31,236 |
Intangible asset amortization | | 37,501 | | | 16,795 | | | 56,424 | | | 33,590 |
Total cost of products revenues |
| 71,185 | | | 32,703 | |
| 106,440 | |
| 64,826 |
Gross profit | | 52,364 | | | 50,239 | | | 100,860 | | | 105,837 |
Operating expenses | | | | | | | | | | | |
Research and development | | — | | | 3,462 | | | 3,983 | | | 6,392 |
Selling, general and administrative |
| 41,254 | |
| 30,368 | |
| 95,782 | |
| 61,844 |
Total operating expenses |
| 41,254 | |
| 33,830 | |
| 99,765 | |
| 68,236 |
Income from operations |
| 11,110 | |
| 16,409 | |
| 1,095 | |
| 37,601 |
Interest expense |
| (17,761) | |
| (5,421) | |
| (23,592) | |
| (11,142) |
Interest income | | 5 | | | 3 | | | 9 | | | 6 |
(Loss) income before income taxes | | (6,646) | | | 10,991 | | | (22,488) | | | 26,465 |
Benefit from income taxes | | (1,455) | | | (61,852) | | | (4,228) | | | (62,040) |
Net (loss) income | $ | (5,191) | | $ | 72,843 | | $ | (18,260) | | $ | 88,505 |
| | | | | | | | | | | |
(Loss) earnings per share — basic | $ | (0.15) | | $ | 2.06 | | $ | (0.54) | | $ | 2.52 |
Weighted-average shares — basic | | 34,001,553 | | | 35,302,608 | | | 33,838,638 | | | 35,128,144 |
| | | | | | | | | | | |
(Loss) earnings per share — diluted | $ | (0.15) | | $ | 1.79 | | $ | (0.54) | | $ | 2.20 |
Weighted-average shares — diluted | | 34,001,553 | | | 41,286,853 | | | 33,838,638 | | | 41,251,749 |
Collegium Pharmaceutical, Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA
(in thousands)
(unaudited)
| | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
| 2022 | | 2021 | | 2022 | | 2021 | ||||
GAAP Net (loss) income | $ | (5,191) | | $ | 72,843 | | $ | (18,260) | | $ | 88,505 |
Adjustments: | | | | | | | | | | | |
Interest expense | | 17,761 | | | 5,421 | | | 23,592 | | | 11,142 |
Interest income | | (5) | | | (3) | | | (9) | | | (6) |
Benefit from income taxes | | (1,455) | | | (61,852) | | | (4,228) | | | (62,040) |
Depreciation | | 656 | | | 425 | | | 1,371 | | | 864 |
Amortization | | 37,501 | | | 16,795 | | | 56,424 | | | 33,590 |
Stock-based compensation expense | | 5,692 | | | 6,516 | | | 11,827 | | | 13,395 |
Acquisition related expense | | 3,579 | | | — | | | 30,746 | | | — |
Recognition of step-up basis in inventory | | 12,638 | | | — | | | 13,241 | | | — |
Total adjustments | $ | 76,367 | | $ | (32,698) | | $ | 132,964 | | $ | (3,055) |
Adjusted EBITDA | $ | 71,176 | | $ | 40,145 | | $ | 114,704 | | $ | 85,450 |
Collegium Pharmaceutical, Inc.
Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
(in thousands)
(unaudited)
| Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
| | 2022 | | | 2021 |
| | 2022 | | | 2021 |
GAAP Operating expenses | $ | 41,254 | | $ | 33,830 | | $ | 99,765 | | $ | 68,236 |
Adjustments: | | | | | | | | | | | |
Stock-based compensation | | 5,692 | | | 6,516 | | | 11,827 | | | 13,395 |
Acquisition related expense | | 3,579 | | | — | | | 30,746 | | | — |
Total adjustments | | 9,271 | | | 6,516 | | | 42,573 | | | 13,395 |
Adjusted operating expenses | $ | 31,983 | | $ | 27,314 | | $ | 57,192 | | $ | 54,841 |
| August 4, 2022 | Nasdaq: COLL Q2FY22 Earnings Report |
| Forward - Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our full-year 2022 financial guidance, including total projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, andother statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations. Actual results may differ materially from management’s expectations and such forward-looking statements in this press release could be affected as a result of various important factors, including risks relating to, among others: risks related to the ability to realize the anticipated benefits of our acquisition of BDSI, including the possibility that the expected benefits from the BDSI acquisition will not be realized or will not be realized within the expected time period; the risk that BDSI’s business will notbe integrated successfully; unknown liabilities; risks related to future opportunities and plans for the products acquired withBDSI, including uncertainty of the expected financial performance of such products; the impact of the COVID-19 pandemic on our ability to conduct our business, reach our customers, and supply the market with our products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain and maintain regulatory approval of our products and any product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product; the size of the markets for our products and product candidates, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement, opioid-related or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P.; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise,after the date of this press release. Non - GAAP Financial Measures To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures such as adjusted EBITDA and adjusted operating expenses. We use these non-GAAP financial measures to understand, manage and evaluate our business as we believe they provide additional information on the performance of our business. We believe that the presentation of these non-GAAP financial measures, taken in conjunction with our results under GAAP, provide analysts, investors, lenders and other thirdparties insight into our view and assessment of our ongoing operating performance. In addition, we believe that the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide supplementary information that may be useful to analysts, investors, lenders, and other third parties in assessing our performance and results from period to period. We report these non-GAAP financial measures to portray the results of our operations prior to considering certain income statement elements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP.In our quarterly and annual reports, earnings press releases and conference calls, we may discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis.Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.There are several limitations related to the use of adjusted EBITDA rather than net income, which is the nearest GAAP equivalent, such as:•adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;•we exclude stock-based compensation expense from adjusted EBITDA although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) ifwedid not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;•adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;•adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes; •adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;•we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contracttermination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business; •we exclude litigation settlements from adjusted EBITDA, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred; •we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after theacquisition, and miscellaneous other acquisition expenses incurred; and•we exclude recognition of the step-up basis in inventory from acquisitions as the amount and/or frequency of these expenses are not part of our underlying business.Adjusted Operating Expenses Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.The Company has not provided a reconciliation of its full-year 2022 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures because it is unable to predict, without unreasonable efforts, thetiming and amountof items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense. These items are uncertainand depend on various factors that could have a material impact on GAAP net income and operating expenses for the guidance period. |
| Buildinga leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions I D E AUpholdI ntegrityEmbrace D ifferencesEncourage E xpressionBe A ccountableGUIDED BY OUR CORE VALUES Mission DrivenInvestor Presentation3 |
| H1 2022 Key Business HighlightsInvestor Presentation G ROW T OP AND B OTTOM L INES Grew Belbuca®and Xtampza®ER prescriptions vs. H1 2021 Completed BDSI acquisition; On track to exceed run rate synergy target Delivered record net revenue $Renegotiated Xtampza ER contracts Resolved all 27 pending opioid industry-related lawsuits 4 |
| Collegium 3-Phase Action Agenda PHASE1SEAMLESSINTEGRATION PHASE2GENERATEMOMENTUM PHASE3ACCELERATE1.Executed with no disruptions to core operations2.Achieved day one field force readiness3.Realized majority of targeted run rate synergies1.Grow Belbuca and Xtampza ER 2.Complete Xtampza ER contract renegotiations3.Achieve remainder of target synergies4.Synthesize Elyxyb™launch learnings1.Propelled by Xtampza ER gross-to-net of <65% in January 20232.Driven by Belbuca and Xtampza ER TRxgrowth3.Bolstered by fully synergized cost structureCOMPLETED7/1/22 –12/31/222023Investor Presentation 5 |
| BUSINESSDEVELOPMENTFOCUS•Differentiated commercial-stage assets•Peak sales potential >$150M•Exclusivity into 2030s Top Capital Allocation Priority: Business Development STRONGTRACKRECORDNucynta Franchise (February 2020)BDSI (March 2022) Investor Presentation6 |
| Financial HighlightsColleen Tupper, Executive Vice President & Chief Financial Officer |
| ESTIMATEDDEBT/EBITDA RATIO<3.0XBY2022 YEAR-END8Q2FY22 Financial Highlights11.This financial data was provided by Collegium Pharmaceutical, Inc. in its Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022.2.Adjusted operating expenses is a non-GAAP financial measure. See Non-GAAP Financial Measures on Slide 2. 3.Adjusted EBITDA is a non-GAAP financial measure. See Non-GAAP Financial Measures on Slide 2. 4.Details regarding the Pharmakon term-loan debt amortization schedule provided by Collegium on form SC TO-C filed with the SEC on February 14, 2022.Investor PresentationRapid Deleveraging3,4 Q2FY22TOTALPRODUCTREVENUE$123.5 MILLION+49% OVERQ2FY21Achieved Record Revenue Q2FY22TOTALADJUSTEDOPEX$32.0 MILLION+17% OVERQ2FY21Leveraged Infrastructure2 |
| Updated 2022 Financial Guidance1$133M1.This financial data was provided by Collegium in its press release filed with the SEC on August 4, 2022.2.Adjusted operating expenses is a non-GAAP financial measure. See Non-GAAP Financial Measures on Slide 2. 3.Adjusted EBITDA is a non-GAAP financial measure. See Non-GAAP Financial Measures on Slide 2. Investor Presentation9 PriorUpdatedTotal Product Revenues$450.0 to $465.0 millionReaffirmedTotal Adjusted Operating Expenses2(Excluding Stock-Based Compensation)$130.0 to $140.0 million$125.0 to $135.0 millionTotal Adjusted EBITDA3(Excluding Stock-Based Compensation and Acquisition Related Expenses)$235.0 to $250.0 million$245.0 to $255.0 million |
| OPPORTUNISTICALLYRETURNCAPITALTOSHAREHOLDERS RAPIDLYPAYDOWNDEBT FOCUSEDBUSINESSDEVELOPMENTCapital Allocation Priorities•Commercial-stage assets:•With $150 million peak sales potential•Differentiated and durable with exclusivity into 2030s•>$50M remaining on $100M share repurchase program2•$650M Pharmakon loan issued on 3/22/222•$100M to be repaid in first 12 months1•>$450M to be repaid in first 36 months1 1231.This financial data was provided by Collegium in its press release issued February 14, 2022.2.This financial data was provided by Collegium in its Form 10-Q filed with the SEC on May 10, 2022.Investor Presentation10 |
| Commercial UpdateScott Dreyer, Executive Vice President & Chief Commercial Officer |
| 122022 Commercial Priorities Maximize Nucynta Franchise and Symproic Launch Elyxyb Achieve gross-to-net of <65% for Xtampza ER beginning in January 2023 Grow Belbuca and Xtampza ER |
| ~19,200 unique prescribers in Q2FY22, up 1% vs. Q2FY21313The Leader in Responsible Pain ManagementInvestor Presentation 49.0%Branded ERMarket Share1,2+3.6% Over Q2FY21 Strong and Growing Market Position ~13,300 unique prescribers in Q2FY22, relatively stable vs. Q2FY213Sources:1.IQVIA NPA through June 20222.Quarter-ending product share (Belbuca, Xtampza ER, and Nucynta ER)3.IQVIA Exponent through June 2022 ~9,200 unique prescribers in Q2FY22,up 7% vs. Q2FY213Large Prescriber Bases |
| Collegium 3-Phase Action Agenda:H1 2022 Commercial Accomplishments and H2 2022 Priorities PHASE1SEAMLESSINTEGRATIONCompleted Investor Presentation141.Executed with no disruptions to core operations2.Achieved day one field force readinessHosted national sales meetingLaunched new Belbuca and Xtampza ER promotional resources3.Realized majority of targeted run rate synergies PHASE2GENERATEMOMENTUM1.Grow Belbuca and Xtampza ERFully trained pain salesforce with only active promotion in painLaser focused on execution of plan to drive prescription growth2.Complete Xtampza ER contract renegotiations3.Achieve remainder of target synergies4.Synthesize Elyxyblaunch learnings7/1/22 –12/31/22 |
| Q&A |
| DIVERSEANDDURABLEPORTFOLIO STRONGFINANCIALPOSITION LONG-TERMVALUECREATION 16Building a Leading, Diversified Specialty Pharmaceutical Company→Durable growth drivers→Leader in responsible pain market→Strategic foothold in neurology→Revenue expected to grow ~65% Y/Y1→Significant cost leverage: revenue expected to grow >2x rate of OPEX1→Est. 2022 YE debt/EBITDA ratio <3.0x1→Focused business development→Rapid debt pay-down →Return capital to shareholders1.Percent change year-over-year, growth rates and financial ratios are calculated based on financial data provided by Collegium onForm 10-Q filed with the SEC on August 4, 2022, compared to the mid-point of the guidance ranges provided by Collegium in its press release filed with the SEC on August 4, 2022. |
| Non-GAAP Reconciliations |
| 18Collegium Pharmaceutical, Inc.Reconciliation of GAAP Net Income to Adjusted EBITDA(in thousands)(unaudited) Three Months Ended June 30,20222021 GAAP Net (loss) income $ (5,191) $ 72,843 Adjustments: Interest expense17,7615,421Interest income (5) (3) Benefit from income taxes (1,455) (61,852) Depreciation656425Amortization37,50116,795Stock-based compensation expense5,6926,516Acquisition related expense3,579—Recognition of step-up basis in inventory12,638—Total adjustments $ 76,367 $ (32,698) Adjusted EBITDA $ 71,176 $ 40,145 |
| 19Collegium Pharmaceutical, Inc.Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses(in thousands)(unaudited) Three Months Ended June 30,20222021 GAAP Operating expenses $ 41,254 $ 33,830 Adjustments: Stock-based compensation5,6926,516Acquisition related expense3,579—Total adjustments9,2716,516 Adjusted operating expenses $ 31,983 $ 27,314 |
